In MM, where clonal evolution and antigen escape pose major challenges, the rational selection of appropriate targets such as BCMA, GPRC5D, NKG2D, CD38, CD70, CD138, and SLAMF7 has become a central focus in advancing CAR-NK therapy (Figure 3). Here, TNFRSF17 is linked to Miyoshi myopathy.